Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation
- PMID: 21493773
- PMCID: PMC3083319
- DOI: 10.1681/ASN.2010070777
Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation
Abstract
In biopsies of renal allografts, arteriosclerosis is often more severe than expected based on the age of the donor, even without a history of rejection vasculitis. To determine whether preformed donor-specific antibodies (DSAs) may contribute to the severity of arteriosclerosis, we examined protocol biopsies from patients with (n=40) or without (n=59) DSA after excluding those with any evidence of vasculitis. Among DSA-positive patients, arteriosclerosis significantly progressed between month 3 and month 12 after transplant (mean Banff cv score 0.65 ± 0.11 to 1.12 ± 0.10, P=0.014); in contrast, among DSA-negative patients, we did not detect a statistically significant progression during the same timeframe (mean Banff cv score 0.65 ± 0.11 to 0.81 ± 0.10, P=not significant). Available biopsies at later time points supported a rate of progression of arteriosclerosis in DSA-negative patients that was approximately one third that in DSA-positive patients. Accelerated arteriosclerosis was significantly associated with peritubular capillary leukocytic infiltration, glomerulitis, subclinical antibody-mediated rejection, and interstitial inflammation. In conclusion, these data support the hypothesis that donor-specific antibodies dramatically accelerate post-transplant progression of arteriosclerosis.
Copyright © 2011 by the American Society of Nephrology
Figures





Similar articles
-
Clinicopathological Analysis of Acute/Active Antibody-Mediated Rejection in Renal Allografts According to the Banff 2013 Classification.Nephron. 2020;144 Suppl 1(Suppl 1):18-27. doi: 10.1159/000512143. Epub 2020 Dec 2. Nephron. 2020. PMID: 33264791 Free PMC article.
-
Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis.Kidney Int. 2017 Sep;92(3):729-742. doi: 10.1016/j.kint.2017.03.033. Epub 2017 May 26. Kidney Int. 2017. PMID: 28554738
-
Replicative senescence and arteriosclerosis after kidney transplantation.Nephrol Dial Transplant. 2020 Nov 1;35(11):1984-1995. doi: 10.1093/ndt/gfaa151. Nephrol Dial Transplant. 2020. PMID: 33067610
-
Reviewing the pathogenesis of antibody-mediated rejection and renal graft pathology after kidney transplantation.Nephrology (Carlton). 2016 Jul;21 Suppl 1:4-8. doi: 10.1111/nep.12777. Nephrology (Carlton). 2016. PMID: 26971899 Review.
-
Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum.Curr Opin Nephrol Hypertens. 2012 May;21(3):264-71. doi: 10.1097/MNH.0b013e3283520efa. Curr Opin Nephrol Hypertens. 2012. PMID: 22388553 Review.
Cited by
-
IMPROVING LONG-TERM OUTCOMES IN KIDNEY TRANSPLANTATION: TOWARDS A NEW PARADIGM OF POST-TRANSPLANT CARE IN THE UNITED STATES.Trans Am Clin Climatol Assoc. 2016;127:350-361. Trans Am Clin Climatol Assoc. 2016. PMID: 28066070 Free PMC article. Review.
-
Current pathological perspectives on chronic rejection in renal allografts.Clin Exp Nephrol. 2017 Dec;21(6):943-951. doi: 10.1007/s10157-016-1361-x. Epub 2016 Nov 16. Clin Exp Nephrol. 2017. PMID: 27848058 Review.
-
Banff 2011 Meeting report: new concepts in antibody-mediated rejection.Am J Transplant. 2012 Mar;12(3):563-70. doi: 10.1111/j.1600-6143.2011.03926.x. Epub 2012 Feb 2. Am J Transplant. 2012. PMID: 22300494 Free PMC article.
-
Role of complement and NK cells in antibody mediated rejection.Hum Immunol. 2012 Dec;73(12):1226-32. doi: 10.1016/j.humimm.2012.07.330. Epub 2012 Jul 28. Hum Immunol. 2012. PMID: 22850181 Free PMC article. Review.
-
The perspective of modern transplant science - transplant arteriosclerosis: inspiration derived from mitochondria associated endoplasmic reticulum membrane dysfunction in arterial diseases.Int J Surg. 2025 May 1;111(5):3430-3440. doi: 10.1097/JS9.0000000000002362. Int J Surg. 2025. PMID: 40146783 Free PMC article. Review.
References
-
- Colvin RB: Antibody-mediated renal allograft rejection: Diagnosis and pathogenesis. J Am Soc Nephrol 18: 1046–1056, 2007 - PubMed
-
- Colvin RB: Renal transplant pathology. In: Heptinstall's Pathology of the Kidney, 6th ed., edited by Jennette JC, Olson JL, Schwartz MM, Silva FG. Philadelphia, Lippincott, Williams & Wilkins, 2007, pp 1347–1490
-
- Cornell LD, Smith RN, Colvin RB: Kidney transplantation: Mechanisms of rejection and acceptance. Annu Rev Pathol 3: 189–220, 2008 - PubMed
-
- Racusen LC, Colvin RB, Solez K, Mihatsch MJ, Halloran PF, Campbell PM, Cecka MJ, Cosyns JP, Demetris AJ, Fishbein MC, Fogo A, Furness P, Gibson IW, Glotz D, Hayry P, Hunsickern L, Kashgarian M, Kerman R, Magil AJ, Montgomery R, Morozumi K, Nickeleit V, Randhawa P, Regele H, Seron D, Seshan S, Sund S, Trpkov K: Antibody-mediated rejection criteria: An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 3: 708–714, 2003 - PubMed
-
- Lefaucheur C, Nochy D, Hill GS, Glotz: Are transplant endarteritis (v1, v2) part of the spectrum of antibody-mediated rejection? [Abstract] 9th Banff Conference on Allograft Pathology, La Coruña, Spain, 2007
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical